Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
P/B ratio for Ikena Oncology, Inc. (IKNA)
P/B ratio as of 2023: 0.48
According to Ikena Oncology, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.48. At the end of 2022 the company had a P/B ratio of 0.65.
P/B ratio history for Ikena Oncology, Inc. from 2018 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.48 |
| 2022 | 0.65 |
| 2021 | 2.17 |
| 2020 | -11.35 |
| 2019 | -18.67 |
| 2018 | -25.03 |